Loss of p53 Attenuates the Contribution of IL-6 Deletion on Suppressed Tumor Progression and Extended Survival in Kras-Driven Murine Lung Cancer
Interleukin-6 (IL-6) is involved in lung cancer tumorigenesis, tumor progression, metastasis, and drug resistance. Previous studies show that blockade of IL-6 signaling can inhibit tumor growth and increase drug sensitivity in mouse models. Clinical trials in non-small cell lung cancer (NSCLC) revea...
Main Authors: | Tan, Xiaohong, Carretero, Julian, Chen, Zhao, Zhang, Jishuai, Wang, Yanxiao, Chen, Jicheng, Li, Xiubin, Ye, Hui, Tang, Chuanhao, Cheng, Xuan, Hou, Ning, Yang, Xiao, Wong, Kwok-Kin |
---|---|
Format: | Online |
Language: | English |
Published: |
Public Library of Science
2013
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3829911/ |
Similar Items
-
Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers
by: Muzumdar, Mandar Deepak, et al.
Published: (2016) -
Fbxw7 Deletion Accelerates KrasG12D-Driven Pancreatic Tumorigenesis via Yap Accumulation123
by: Zhang, Qiang, et al.
Published: (2016) -
KRAS-driven ROS promote malignant transformation
by: Suh, Yongjoon, et al.
Published: (2015) -
MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells
by: Kharbanda, Akriti, et al.
Published: (2014) -
Unique volatolomic signatures of TP53 and KRAS in lung cells
by: Davies, M P A, et al.
Published: (2014)